Abbott Labs (NYSE:ABT) is set to report its Q4 2018 earnings on January 23, and we expect the company to post steady growth, primarily led by its Cardiovascular & Neuromodulation, as well as Diagnostics segments. We forecast a mid-single digit revenue growth for the company and earnings to be over $0.80 per share in Q4. We have created an interactive dashboard ~ What Is The Q4 Outlook For Abbott ~ on the company’s expected performance in the quarter. Diagnostics revenues have seen strong growth in 2018, primarily due to the impact of the Alere acquisition, which was closed in Q4 2017. However, we forecast the margins to improve to 18% in Q4, led by continued cost reductions, and merger synergies, among other factors.

Source: Forbes January 22, 2019 20:15 UTC